Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100984 · ClinicalTrials.gov registry record · Phase 4
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
A Phase 4 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT00100984 is a Phase 4 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 8 participants.
The verdict
NCT00100984, a Phase 4 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
The main objective of this study is to compare the safety and efficacy of an enfuvirtide containing regimen to a nucleoside combination regimen. Resistance information will also be collected.
Interventions
- DRUG FUZEON [enfuvirtide]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2004-07-21 |
| Est. Completion | 2005-07-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00100984
The ClinicalTrials.gov registry entry for NCT00100984 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FUZEON [enfuvirtide] is the first listed.
NCT00100984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00100984 about?
NCT00100984 is a clinical study titled "A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1". The main objective of this study is to compare the safety and efficacy of an enfuvirtide containing regimen to a nucleoside combination regimen. Resistance information will also be collected.
What is the current status of trial NCT00100984?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2004-07-21. Estimated completion is 2005-07-16.
What interventions are being tested in trial NCT00100984?
The interventions under investigation include: FUZEON [enfuvirtide] (DRUG).
Who is sponsoring clinical trial NCT00100984?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.